Fingerprint
Dive into the research topics of 'Evaluation of [ 89 Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Evaluation of [ 89 Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer
Farrokh Dehdashti, Ningying Wu, Ron Bose, Michael J. Naughton, Cynthia X. Ma, Bernadette V. Marquez-Nostra, Philipp Diebolder, Cedric Mpoy, Buck E. Rogers, Suzanne E. Lapi, Richard Laforest, Barry A. Siegel
- Division of Nuclear Medicine
- Institute of Clinical and Translational Sciences (ICTS)
- Siteman Cancer Center
- Section of Medical Oncology
- Roy and Diana Vagelos Division of Biology & Biomedical Sciences (DBBS)
- Department of Radiology
- Section of Molecular Oncology & Developmental Therapeutics
- Division of Cancer Biology
- Precision Radiotheranostics Translation Center (PRTC)
- Rheumatic Diseases Research Resource-Based Center
- DBBS - Molecular Cell Biology
- DBBS - Biochemistry, Biophysics, and Structural Biology
- DBBS - Cancer Biology
- Bursky Center for Human Immunology & Immunotherapy Programs (CHiiPs)
Research output: Contribution to journal › Article › peer-review
64
Scopus
citations